Completed NA INTERVENTIONAL NCT00114855

The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose

A Single-Centre, Randomised Double-Blind Placebo-Controlled Study to Measure the Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose

Sponsor: Beijing Peking University WBL Biotech Co., Ltd.

Conditions Glucose Metabolism Disorders Hyperlipidemia

Interventions HYPOCOL®

Updated 5 times since 2017 Last updated: Jul 3, 2011 Started: Mar 31, 2005 Primary completion: Dec 31, 2005 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Glucose Metabolism Disorders and Hyperlipidemia and is currently completed. Beijing Peking University WBL Biotech Co., Ltd. leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Peking University WBL Biotech Co., Ltd.
Oslo University Hospital
Pharmalogica
Wearnes Biotech @ Medicals

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway